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Although macrophages are widely recognized to have a proﬁbrotic
role in inﬂammation, we have used a highly tractable CCl4-induced
model of reversible hepatic ﬁbrosis to identify and characterize the
macrophage phenotype responsible for tissue remodeling: the hith-
erto elusive restorative macrophage. This CD11Bhi F4/80int Ly-6Clo
macrophage subset was most abundant in livers during maximal ﬁ-
brosis resolution and represented the principle matrix metalloprotei-
nase (MMP) -expressing subset. Depletion of this population in
CD11B promoter–diphtheria toxin receptor (CD11B-DTR) transgenic
mice caused a failure of scar remodeling. Adoptive transfer and
in situ labeling experiments showed that these restorative macro-
phages derive from recruited Ly-6Chi monocytes, a common origin
with proﬁbrotic Ly-6Chi macrophages, indicative of a phenotypic
switch in vivo conferring proresolution properties. Microarray pro-
ﬁling of the Ly-6Clo subset, compared with Ly-6Chi macrophages,
showed a phenotype outside the M1/M2 classiﬁcation, with
increased expression of MMPs, growth factors, and phagocyto-
sis-related genes, including Mmp9, Mmp12, insulin-like growth
factor 1 (Igf1), and Glycoprotein (transmembrane) nmb (Gpnmb).
Confocal microscopy conﬁrmed the postphagocytic nature of re-
storative macrophages. Furthermore, the restorative macrophage
phenotype was recapitulated in vitro by the phagocytosis of cel-
lular debris with associated activation of the ERK signaling cas-
cade. Critically, induced phagocytic behavior in vivo, through
administration of liposomes, increased restorative macrophage
number and accelerated ﬁbrosis resolution, offering a therapeutic
strategy to this orphan pathological process.
Kupffer Cell | collagen | degradation | myoﬁbroblast | proliferation
As the generic and common pathological endpoint to chronicinjury, ﬁbrosis has been estimated to contribute to 45% of
all deaths in industrialized nations (1, 2). Currently, no direct
antiﬁbrotic therapeutic interventions exist. Long thought of as
inexorably progressive, recent evidence, particularly in the liver
(3) but also the kidney (4), lung (5, 6), and heart (7), indicates
that some reversibility exists, even in advanced disease. There-
fore, a more detailed understanding of the speciﬁc mechanisms
governing ﬁbrosis regression will likely inform therapeutic
approaches.
Macrophages have long been implicated in promoting tissue ﬁ-
brosis (8–10). However, it has recently been shown that they also
play a pivotal role in ﬁbrosis regression (6, 11), in part through ex-
pression of matrix-degrading metalloproteinase enzymes (MMPs)
(12). Macrophages are capable of distinct activation states and
functions, which in vitro, can be broadly classiﬁed asM1 (classical)
or M2 (alternative) (13, 14). It is generally postulated that M1
macrophages are proinﬂammatory, whereas M2 macrophages are
responsible for immunomodulation and wound-healing responses
(14). However, it is increasingly clear that this binary classiﬁcation
does not address the more complex heterogeneity in vivo, where
macrophages adopt distinct phenotypes and even switch between
phenotypes in response to the myriad of stimuli to which they are
exposed (13). These in vivo macrophage phenotypes are impos-
sible to recapitulate exactly in tissue culture models, emphasizing
the importance of the characterization of macrophages on the
basis of function (13).
Ly-6C is a cell surface glycoprotein that is widely used to
identify functionally discrete murine circulating monocyte pop-
ulations: Ly-6Chi monocytes (analogous to CD14hi CD16lo human
monocytes) are recruited early to inﬂammatory environments
and thought to be proinﬂammatory, whereas Ly-6Clo monocytes
(analogous to CD14lo CD16hi human monocytes) are a more
patrolling cell type and can replenish resident tissue macrophages
(15, 16). Differential Ly-6C expression in diseased tissues has
identiﬁed functionally distinct macrophage populations (17–20).
Indeed, an Ly-6Chi intrahepatic macrophage population, derived
from recruitment of circulating Ly-6Chi monocytes, is critical for
ﬁbrogenesis (21). However, the nature, origin, and phenotype of
the macrophage subset responsible for mediating ﬁbrosis reso-
lution have not been deﬁned.
In this study, we have exploited differential Ly-6C expression
in a tractable and reproducible model of reversible murine he-
patic ﬁbrosis to identify the speciﬁc macrophage population re-
sponsible for ﬁbrosis resolution: the restorative macrophage. We
have gone on to characterize this cell, and we have shown cate-
gorically that it is derived from recruited inﬂammatory mono-
cytes after a phenotypic switch mediated by the ingestion of
cellular debris and that it represents a newly identiﬁed phenotype
distinct from the M1/M2 paradigm. Finally, we have established
this mechanism to manipulate macrophage phenotype in vivo
and accelerate ﬁbrosis resolution.
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Results
Experimental Liver Fibrosis Shows Distinct Phases of Fibrogenesis and
Resolution.We established a model of liver ﬁbrosis reversal from
which macrophage populations could be isolated on a day-to-day
basis. C57BL/6 mice were administered two times weekly i.p.
carbon tetrachloride (CCl4) for 4 wk followed by tissue harvests
24, 48, 72, 96, 168, and 256 h after the ﬁnal CCl4 injection
(Fig. 1A). Comparison was made with age-matched uninjured
(control) animals. Hepatic ﬁbrosis and myoﬁbroblast activation
were assessed by immunohistochemistry and morphometric
analysis of picrosirius red (PSR), collagen 1, collagen 3, and
α-smooth muscle actin (α-SMA). Liver ﬁbrosis and myoﬁbroblast
activation (α-SMA) peaked at 48–72 h, identifying 24 h as a time
of active ﬁbrogenesis, whereas maximal scar resolution and re-
duction in myoﬁbroblast area occurred between 72 and 96 h and
was followed by a more protracted regression of the residual
ﬁbrosis (96–256 h) (Fig. 1 B and C). Scar resolution occurred
after reduction in overall hepatic damage as assessed by serum
alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) levels (Fig. 1D). Additionally, at the initiation of scar
resolution, there was a signiﬁcant reduction in hepatic levels of
Il-1β, Ccl2, Ccl3, and Cxcl2, suggesting an overall change in
macrophage phenotype (Fig. 1E). As we have previously shown
(3), loss of liver Timp-1 at a gene and protein level preceded
ﬁbrosis regression (Fig. S1 A and B).
Ly-6Clo Monocyte-Derived Macrophages Predominate During Maximal
Fibrosis Resolution and Represent the Principle MMP-Expressing Subset.
Having identiﬁed the time of early and maximal ﬁbrosis resolu-
tion (72 h), we determined whether there were associated
changes in speciﬁc hepatic macrophage subsets. Total hepatic
macrophages were identiﬁed on ﬂow cytometry as viable CD45+
Ly-6G− NK1.1− CD3− B220− CD11B+ F4/80+ cells from the
nonparenchymal cell fraction of digested livers (Fig. S2 A–E).
Importantly, coinciding with maximal ﬁbrosis resolution, total
hepatic macrophage number peaked at 72 h (Fig. 2A), and
macrophages closely associated with hepatic scars topographi-
cally (Fig. 2B).
Flow cytometric analysis of hepatic macrophages enabled
identiﬁcation of distinct subsets. F4/80hi CD11Bintermediate mac-
rophages predominated in the control (uninjured) liver and rep-
resent the resident Kupffer cell population (22) (Fig. 2C). The
proportion of resident macrophages was reduced during active
inﬂammation/ﬁbrogenesis (24 h) and progressively increased
during resolution (Fig. 2 C and E). The CD11Bhi F4/80intermediate
subset represents a recruited monocyte-derived macrophage
population (22). Analysis of Ly-6C expression on this subset
identiﬁed two clearly distinct hepatic recruited macrophage pop-
ulations: Ly-6Chi and Ly-6Clo (Fig. 2D). Dynamic changes in these
macrophage populations were seen during ﬁbrogenesis and reso-
lution (Fig. 2 D and E). Whereas during ﬁbrogenesis (24 h), Ly-
6Chi (proﬁbrotic) macrophages were the predominant subset (21)
(Fig. 2E), at maximal scar resolution (72 h), when macrophage
number peaked, there was a reduction in the Ly-6Chi population
and a dramatic and signiﬁcant increase in Ly-6Clo macrophages,
which became the dominant population (Fig. 2E). Overall, these
changes were also evident when absolute macrophage numbers
were quantiﬁed (Fig. 2F). Therefore, Ly-6Clo monocyte-derived
macrophages at the time of maximal scar resolution represented
the most numerous macrophage population seen throughout the
injury and recovery phases (4.13 ± 0.5-fold more than the total
number of macrophages in the undamaged liver).
During late resolution (168 h), the relative proportions of mac-
rophage subsets returned to control liver, although there re-
mained an increase in the proportion of the Ly-6Clo subset (Fig.
2E).We have previously shown that macrophageMMP expression
is critical for ﬁbrosis regression (12). To identify the principle
hepaticMMP-expressingmacrophage subset, we used a pan-MMP
substrate (MMPsense), which becomes ﬂuorescent after cleavage
by activeMMPs in vivo (23), enabling us to identify a population of
MMPsense-positive hepatic macrophages by ﬂow cytometry (Fig.
Fig. 1. Experimental liver ﬁbrosis shows distinct phases of ﬁbrogenesis and
resolution. (A) Schematic representation of the model of reversible hepatic
ﬁbrosis in C57BL/6 mice by 4 wk of two times per week i.p. CCl4 followed by
harvest at serial time points after the ﬁnal injection. Comparisons were
made with control (uninjured) animals. (B and C) Histological characteriza-
tion of hepatic ﬁbrosis and myoﬁbroblast activation by PSR, collagen 1,
collagen 3, and α-SMA immunohistochemistry. (B) Representative images
are shown for control animals and each time point. (Scale bar: 100 μm.) (C)
Quantiﬁcation of histological changes by morphometric pixel analysis ex-
pressed relative to mean percent area of control animals (n = 4 per time
point; representative of three independent experiments). (D) Serum ALT and
AST levels in control mice and at stated time point after the ﬁnal CCl4 dose
(n = 5–6 per time point from two independent experiments). (E) Whole-liver
protein levels of Il-1β, Ccl2, Ccl3, and Cxcl2 measured by multiplex cytokine
assay expressed relative to mean protein concentration at the 24-h time
point for each (n = 7–9 per time point from two independent experiments).
All data shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.

















2G). Subset analysis of these cells during both ﬁbrogenesis (24 h)
and maximal matrix degradation (72 h) showed that the pre-
dominant active MMP-expressing macrophage population at both
time points was the Ly-6Clo macrophage (Fig. 2H). Therefore, Ly-
6Clo monocyte-derived macrophages accumulate maximally dur-
ing the most rapid phase of ﬁbrosis resolution. Furthermore, they
represent the principle MMP-expressing population during both
ﬁbrogenesis and ﬁbrosis regression.
Depletion of CD11B-Positive Macrophages Deﬁnes Ly-6Clo Cells as
Being Critical for Scar Resolution. To deﬁne the functional role of
distinct macrophage subsets in mediating scar resolution, a well-
described selective in vivo macrophage depletion strategy was
used (11). CD11B promoter - diphtheria toxin receptor (CD11B-
DTR) transgenic mice were given CCl4 for 4 wk. To ensure
maximal macrophage depletion throughout the rapid phase of
scar resolution, i.v. diphtheria toxin (DT) (or PBS control) was
administered 48, 72, and 96 h after the ﬁnal CCl4 injection fol-
lowed by harvest at 120 h (Fig. 3A). In concordance with previous
data (17), administration of DT was effective in depleting both
populations of circulating monocytes (Ly-6Chi and Ly-6Clo) (Fig.
S3 A and B). The degree of depletion was more profound for the
Ly-6Clo monocytes in keeping with them being a more mature cell
type forming from differentiation of Ly-6Chi monocytes (15) and
thus, taking longer to replenish after depletion (24).
We proceeded to analyze hepatic macrophage subsets in
CD11B-DTR mice (Fig. 3 B and C). Importantly, administration
of DT during maximal ﬁbrosis resolution, when Ly-6Clo intra-
hepatic macrophages predominate, induced signiﬁcant depletion
of this subset until harvest, causing a 76.7 ± 3.16% reduction in
relative number at 120 h (Fig. 3 B and C). No depletion of the
smaller population of hepatic Ly-6Chi macrophages was seen,
whereas there was a minor increase in the resident macrophage
number (Fig. 3C). For comparison, we depleted macrophages
during the inﬂammatory/ﬁbrogenic phase when both Ly-6Chi and
Ly-6Clo hepatic macrophages are present in large numbers. DT
was administered to CD11B-DTR mice 8 h after ﬁnal CCl4, with
harvest at 24 h. Using this strategy, we observed a more general
depletion of both Ly-6Chi and Ly-6Clo monocyte-derived mac-
rophage subsets (Fig. S3C). Thus, timing depletion for when an
individual population predominates is critical for selectivity.
What is also apparent from these data is that the Ly-6Clo hepatic
macrophage subset is more susceptible to depletion after DT
than the Ly-6Chi subset. This result is likely to reﬂect the higher
level of CD11B expression in Ly-6Clo macrophages than the Ly-
6Chi subset (Fig. S3D). Importantly, DT administration during
ﬁbrosis regression did not induce a change in the number of
hepatic neutrophils or CD3-positive cells (Fig. S3 E and F).
Furthermore, this depletion strategy caused persistent ﬁbrosis,
indicating a failure to remodel the hepatic scar (Fig. 3 D and E).
No difference was detected in the α-SMA area after macrophage
depletion, suggesting that the observed phenotype was a result of
reduced matrix degradation rather than increased myoﬁbroblast
activation (Fig. 3 D and E). To conﬁrm the speciﬁcity of these
ﬁndings, we administered DT (or PBS control) to WT mice
according to the same schedule (Fig. 3A). DT administration to
WT mice had no effect on macrophage subsets or hepatic ﬁbrosis
(Fig. S3 G and H). To further show the speciﬁc effect of hepatic
Ly-6Clo macrophages on ﬁbrosis regression, we identiﬁed a sta-
tistically signiﬁcant inverse correlation between the number of
Ly-6Clo macrophages and the degree of ﬁbrosis (Fig. 3F), indi-
cating that the degree of depletion of this subset directly relates
to the amount of residual scar. Critically, no signiﬁcant correla-
tions were seen between the number of Ly-6Chi or resident
macrophages and the degree of ﬁbrosis (Fig. S3 I and J).
These ﬁndings indicate that Ly-6Clo macrophages are critical
for the resolution of hepatic ﬁbrosis and the restoration of normal
tissue architecture. Furthermore, given the temporal and nu-
merical association of the Ly-6Clo subset with the time of maximal
scar degradation (Fig. 2 D–F) and the fact that they are the
principle MMP-expressing population (Fig. 2H), we postulated
that these represent the elusive restorative macrophages.
Fig. 2. Ly-6Clo macrophages predominate during maximal ﬁbrosis resolu-
tion and represent the principle MMP expressing subset. (A–G) Analysis of
hepatic macrophages at 24 (inﬂammation/ﬁbrogenesis), 72 (early and max-
imal scar resolution), and 168 h (late resolution) after the ﬁnal CCl4 injection.
Comparison was made to control (uninjured) mice. (A) Total hepatic mac-
rophage number quantiﬁed by ﬂow cytometry expressed relative to the
mean number of macrophages in control liver (n = 8–12 per time point from
two independent experiments). (B) F4/80 immunohistochemistry indicates
that macrophages localize around areas of scar at 72 h. (Scale bar: 100 μm.)
(C) F4/80hi CD11Bint resident Kupffer cells during injury and resolution
(representative percentages indicate F4/80hi CD11Bint cells as a proportion of
total macrophages). (D) Subset analysis of CD11Bhi F4/80int monocyte-de-
rived macrophages on the basis of differential Ly-6C expression identiﬁes
two distinct populations: Ly-6Chi and Ly-6Clo with dynamic changes during
injury and resolution (representative percentages indicate each subset as
a proportion of total hepatic macrophages). (E) Quantiﬁcation of Ly-6Chi, Ly-
6Clo, and resident macrophage subsets as a proportion of total hepatic
macrophage number (n = 10–17 per time point from four independent
experiments). (F) Relative number per liver of each macrophage subset at
each time point expressed relative to mean total macrophage number in
control liver (n = 12–17 per time point from four independent experiments).
(G and H) After 4 wk of CCl4, mice were given ﬂuorescent MMP substrate
(MMPsense) or vehicle control at 0 or 48 h with harvest at 24 or 72 h, re-
spectively. (G) Identiﬁcation of MMPsense-positive macrophages at 24 and
72 h by ﬂow cytometry. (H) Macrophage subset analysis of MMPsense-pos-
itive macrophage population at 24 and 72 h (n = 3–4). All data shown as
mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Representative ﬂow
cytometry plots, histograms, and images are shown.
E3188 | www.pnas.org/cgi/doi/10.1073/pnas.1119964109 Ramachandran et al.
CD11c+ dendritic cells (DCs) have been associated with res-
olution of liver injury (25, 26) and share a number of cell surface
markers with macrophages (27). The restorative macrophage
subset at 72 h expressed only intermediate levels of CD11c (Fig.
S4A). Furthermore, administration of DT to chronically injured
CD11c-DOG mice at a dose known to deplete hepatic DCs (28)
had no effect on the identiﬁed hepatic macrophage subsets (Fig.
S4 B and C), indicating no signiﬁcant contribution of hepatic DCs
to these populations.
Ly-6Clo Macrophages Derive from an in Situ Phenotypic Switch of
Recruited Ly-6Chi Monocytes. The proﬁbrotic Ly-6Chi macrophage
subset has been shown to derive from a Chemokine (C-C motif)
receptor 2 (CCR2)-dependent recruitment of circulating Ly-6Chi
monocytes (21). Given that hepatic Ly-6Clo macrophages are also
monocyte-derived (Fig. 2D), restorative macrophages must have
an origin from recruited Ly-6Chi or Ly-6Clo monocytes. Blood
analysis showed that, during active ﬁbrogenesis (24 h), there was
an increased number of both populations of circulating mono-
cytes, whereas during maximal resolution (72 h), only the Ly-6Chi
monocytes remained elevated (Fig. S5 A–C).
To determine which of the circulating monocyte populations
contributed to the formation of the restorative macrophages,
adoptive transfer and in vivo labeling experiments were per-
formed. For adoptive transfer, hepatic ﬁbrosis was induced in
C57BL/6 mice (CD45.2+); 4 h after the ﬁnal CCl4 injection, we
injected 9 × 105 FACS-sorted bone marrow-derived CD45.1+ Ly-
6Chi monocytes (Ly-6G− CD115+ CD11B+ Ly-6Chi cells) (Fig.
S5D) or vehicle control through the tail vein, with harvests at 24,
72, and 168 h (Fig. 4A). Adoptively transferred CD45.1+ Ly-6Chi
monocytes could be detected in livers during active ﬁbrogenesis
(24 h) and early resolution (72 h) but not during late resolution
(Fig. 4B). Even at 24 h, these monocytes had differentiated into
Ly-6Clo macrophages (Fig. 4 C–E). This population remained the
predominant macrophage population formed from the adoptively
transferred monocytes at 72 h (Fig. 4 C–E). To determine the
relative contribution of Ly-6Clo monocytes to the hepatic mac-
rophage subsets, we used a well-validated in vivo labeling tech-
nique (29, 30). After chronic injury with 4 wk of CCl4, mice were
given 200 μL ﬂuorescent latex beads (which selectively label cir-
culating Ly-6Clo monocytes) through the tail vein 4 h after the
ﬁnal CCl4 injection. Animals were harvested at 24, 72, and 168 h
(Fig. 4F). This technique caused selective labeling of circulating
Ly-6Clo monocytes (Fig. S5 E and F) as previously shown (29, 30).
Latex-positive cells could not be identiﬁed in livers at 24 or 72 h,
despite concurrent positive circulating Ly-6Clo monocytes (Fig.
4G). However, a population of intrahepatic latex-positive cells
emerged during late resolution (168 h) (Fig. 4H), predominantly in
the resident macrophage population (Fig. 4 H and I).
Recent work has also shown a key role for local proliferation in
the accumulation of macrophages during chronic inﬂammation
(31). Given the dramatic increase in the number of Ly-6Clo mac-
rophages at maximal resolution (Fig. 2F), we determined the
contribution of local macrophage proliferation to this population.
Using ﬂow cytometric Ki-67 staining on hepatic nonparenchymal
cells after 4 wk of CCl4, we could identify proliferative hepatic
macrophages (Fig. 4J). Interestingly, the recruited proinﬂam-
matory Ly-6Chi macrophage population represented the most
proliferative macrophage subset at 24, 72, and 120 h after the ﬁnal
CCl4 injection (Fig. 4K). The fact that the number of Ly-6C
hi
macrophages rapidly declines (Fig. 2 E and F) in the context of
active proliferation emphasizes that this population undergoes a
switch in phenotype in vivo.
These data show that restorative Ly-6Clo macrophages derive
from circulating Ly-6Chi monocytes, a common origin to proﬁ-
brotic macrophages, and that an in vivo phenotypic switch leads
to ﬁbrosis-modifying capabilities. Furthermore, Ly-6Clo mono-
cytes make no contribution to the proresolution population but
contribute to repopulating the resident macrophage pool during
late resolution.
Ly-6Clo Macrophages Show a Characteristic Gene Expression Proﬁle
Favoring Scar Resolution. Having identiﬁed that Ly-6Clo macro-
phages, derived from a phenotypic switch of Ly-6Chi monocytes,
are critical for regression of hepatic ﬁbrosis, we sought to deﬁne
the mediators produced by this newly identiﬁed macrophage
subset that confer its restorative properties. Affymetrix mouse
gene microarrays were performed on FACS-sorted restorative 72-
h Ly-6Clo macrophages and compared with the proﬁbrotic 24-h
Ly-6Chi macrophages given their common origin, distinct func-
tional roles, and relative predominance at critical time points in
Fig. 3. Depletion of CD11B-positive macrophages deﬁnes Ly-6Clo cells as
being critical for scar resolution. (A) Schematic representation of model of
macrophage depletion during ﬁbrosis resolution in CD11B-DTR mice by ad-
ministration of DT (or PBS control). (B) Flow cytometry data from livers of
PBS and DT-treated mice gated on viable CD45+ Ly-6G− CD11Bhi F4/80int
hepatic macrophages (representative percentages of each subset as a pro-
portion of total macrophage number shown). (C) Quantiﬁcation of relative
number of each macrophage subset expressed relative to mean total mac-
rophage number in PBS-treated livers (n = 11–13 from two independent
experiments). (D) Representative PSR staining and immunohistochemistry
of collagen 1, collagen 3, and α-SMA after macrophage depletion or control.
(Scale bar: 100 μm.) (E) Quantiﬁcation of histological changes by pixel
analysis expressed relative to mean percent area in PBS-treated liver (n = 10–
12 from two independent experiments). (F) Correlation of degree of ﬁbrosis
assessed by PSR, collagen 1, and collagen 3 area with the relative number of
Ly-6Clo macrophages (n = 22 from two independent experiments). All data
shown as mean ± SEM. *P < 0.05, ***P < 0.001. NS, nonsigniﬁcant. Repre-
sentative ﬂow cytometry plots and images are shown.

















the ﬁbrogenesis resolution model. Speciﬁc microarray hits were
conﬁrmed by quantitative PCR.
A number of differentially regulated genes were identiﬁed, and
the full list is available in Tables S1 and S2. In keeping with the
critical role of macrophage MMP expression in ﬁbrosis resolu-
tion (12), the switch to a proresolution macrophage phenotype
was associated with an up-regulation of MMPs (Fig. 5A). Fur-
thermore, a number of proinﬂammatory cytokines and chemo-
kines were down-regulated, and concurrently, genes associated
with an antiinﬂammatory macrophage program [e.g. Chemokine
(C-X3-C) receptor 1 (CX3CR1)] (32) or antiﬁbrotic effects (e.g.
Macrophage migration inhibitory factor (MIF) and CD74) (33)
were increased (Fig. 5A). Expression of TGF-β, the archetypal
proﬁbrotic cytokine, was reduced in the restorative macrophage
population along with Thrombospondin-1 (Thbs1), a potent
activator of latent TGF-β (34). We also identiﬁed additional pro-
resolution mechanisms, such as a strong increase in expression of
insulin-like growth factor 1 (Igf1), which has been implicated as
being antiﬁbrotic (35) (Fig. 5A). Thus, the switch to a restorative
macrophage phenotype confers a number of proresolution fea-
tures, highlighting the importance of a cellular mechanism for
tissue ﬁbrosis regression.
We performed pathway enrichment analysis on the differen-
tially regulated genes from the two macrophage populations using
the DAVID bioinformatics tool (36, 37). The proinﬂammatory
macrophage population was enriched for pathways, including
response to wounding, coagulation cascade, and chemotaxis (Fig.
S6A), which are important for ﬁbrogenesis (38, 39). Analysis of the
restorative macrophages showed enrichment for pathways, such as
lysosomes, endocytosis, scavenger receptors, and antigen pre-
sentation, which are implicated in phagocytosis (Fig. S6B).
We also identiﬁed enhancement of pathways implicated in fatty
acid metabolism and peroxisome proliferator activated receptor
(PPAR) signaling (Fig. S6B). The enrichment of phagocytosis-
related genes was conﬁrmed individually, where a number of
opsonins, receptors, and genes involved in the recognition, bind-
ing, and clearance of apoptotic cells were up-regulated in the re-
storative macrophage population (Fig. 5B). Similarly, a number of
PPAR-γ target genes was up-regulated in these proresolution
macrophages (Fig. 5B). We also assessed the degree of expression
of a number of previously described M1 and M2 macrophage
markers to determine how hepatic inﬂammatory and restorative
macrophages ﬁt into the traditional paradigm (Fig. 5 A and B).
Although Ly-6Clo restorative macrophages show increased ex-
pression of some M2 genes, such as Macrophage Mannose
receptor 1 (Mrc1), Arginase-1 (Arg1), and Retnla (Fizz-1), they
also down-regulate other characteristic M2 genes, including
Chi3l3 (YM-1), Il-1 receptor antagonist (Il1rn), Kdm6b (Jmjd3),
Ccl24, Il-10, and TGF-β (14, 40). Simultaneously, these Ly-6Clo
macrophages up-regulate traditional M1 genes, such as Ciita
(MHC class II transactivator), CD16, CD32, and Serpine1 (plas-
minogen activator inhibitor type 1) (14, 40, 41). Therefore, these
hepatic macrophage populations do not ﬁt into the M1/M2 clas-
siﬁcation and represent newly identiﬁed macrophage phenotypes
(Fig. 5B).
We proceeded to conﬁrm a number of the gene expression
changes at a protein level using ﬂow cytometry (Fig. 5C). Ad-
ditionally, by administering MMPsense 24 h before harvest, we
showed that the switch from inﬂammatory to restorative mac-
rophage phenotype resulted in an increase in active MMP ex-
pression (Fig. 5C). Our microarray data also enabled us to
identify the functionally distinct macrophage subsets in situ
using immunohistochemistry for Chi3l3, MMP-12, and Glyco-
protein (transmembrane) nmb (Gpnmb) (Fig. 5D). We con-
ﬁrmed the speciﬁcity of these markers in our CD11B-DTR
depletion model, where the administration of DT causes a sig-
niﬁcant reduction in the number of MMP-12–positive cells
histologically (Fig. S6C), whereas there was no signiﬁcant dif-
ference in the number of Chi3l3-positive cells (Fig. S6D), mir-
roring the changes seen on ﬂow cytometry (Fig. 3 B and C). We
went on to show the presence of similar MMP-12– and GPNMB-
expressing cells associated with scars in cirrhotic human livers
(Fig. 5D) and have identiﬁed them as a subpopulation of human
CD68-positive macrophages (Fig. S6 E and F).
Fig. 4. Ly-6Clo hepatic macrophages derive
from recruited Ly-6Chi monocytes. (A) Schematic
representation of the model of adoptive trans-
fer of CD45.1+ Ly-6Chi monocytes (or vehicle
control) into C57BL/6 mice (CD45.2+) 4 h after
the ﬁnal CCl4 injection, with livers harvested at
24, 72, and 168 h. (B) Identiﬁcation of injected
CD45.1+ cells in digested livers at 24 and 72 h
time points (gating on viable CD45.2− cells).
(C) Hepatic CD45.1+ cells have predominantly
differentiated into CD11Bhi F4/80int monocyte-
derived macrophages. (D) CD45.1+ monocytes
have largely formed the restorative Ly-6Clo
macrophage subset. (E) Quantiﬁcation of the
proportion of identiﬁed CD45.1+ hepatic mac-
rophages forming each of the macrophage
subsets (n = 3 per time point). (F) Schematic
representation of the model of in situ labeling
of circulating Ly-6Clo monocytes by injection of
ﬂuorescent latex beads (or vehicle control) 4 h
after the ﬁnal CCl4 injection. (G) Latex-positive
macrophages are identiﬁed in the liver only at
168 h (gating on viable CD45+ Ly-6G− hepatic
macrophages). (H) Latex-positive cells have
formed the resident CD11bint F4/80hi macro-
phage population. (I) Quantiﬁcation of the pro-
portion of latex-positive cells forming each of the
hepatic macrophage subsets at 168 h (expressed
as a percent of latex-positive cells; n = 4). (J and
K) Ki-67 staining of hepatic macrophages 24, 72,
and 120 h after ﬁnal CCl4 dose after 4 wk of injury. (J) Ki-67–positive macrophages identiﬁed by ﬂow cytometry. (K) Percentage of the stated macrophage subset
at the indicated time point identiﬁed as Ki-67–positive (n = 3–6). All data shown as mean ± SEM. *P < 0.05, ***P < 0.001. Representative ﬂow cytometry plots and
proportions are shown.
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These data indicate that the phenotypic switch to the restorative
macrophage population results in a loss of proinﬂammatory gene
expression, increased expression of matrix-degrading enzymes,
and enrichment of phagocytosis-related genes. Furthermore, the
identiﬁed macrophage phenotypes fall outside the M1/M2 para-
digm, highlighting the limitations of this classiﬁcation in an in
vivo setting.
Restorative Ly-6Clo Macrophages Are Postphagocytic. Having iden-
tiﬁed up-regulation of phagocytosis-related pathways, we de-
termined if restorative macrophages were postphagocytic. It is
recognized that ingestion of cellular debris can inﬂuence mac-
rophage phenotype (42). Furthermore, the switch to ﬁbrosis res-
olution in our model followed a reduction in hepatocyte death as
assessed by serum ALT and AST (Fig. 1D), indicating that the
increase in the restorative Ly-6Clo population (Fig. 2 E and F)
occurred after the clearance of cellular debris.
Flow cytometric and immunohistochemical analysis showed
that, compared with the proinﬂammatory 24-h Ly-6Chi macro-
phages, restorative 72-h Ly-6Clo macrophages were larger [for-
ward scatter area (FSC-A)], were more complex [side scatter
area (SSC-A)], and showed features of being postingestion (Fig.
6 A and B). We FACS sorted these two macrophage subsets and
TUNEL stained each to quantify the presence of intra- or ex-
tracellular apoptotic debris using confocal microscopy (Fig. 6C).
No difference was seen in the percentage of each macrophage
subset associated with TUNEL-positive debris (Fig. 6D). How-
ever, in the proinﬂammatory macrophages, apoptotic debris was
predominantly bound to the cell surface, whereas in the re-
storative macrophage subset, the debris had been ingested (Fig.
6 C and E), conﬁrming the postphagocytic phenotype of the Ly-
6Clo macrophage population. These ﬁndings are consistent with
the known ability of monocytes to bind apoptotic debris, but a
delayed capacity to ingest until differentiation into a more ma-
ture macrophage subtype has occurred (43, 44).
Macrophage Phagocytosis in Vitro Induces a Matrix-Degrading
Phenotype Through ERK Signaling. Having identiﬁed evidence of
prior phagocytosis as a key feature of the restorative macrophage
population, we sought to model this phenotype in vitro. Given
that the predominant cellular debris in the CCl4 model is hepa-
tocyte-derived, we determined whether ingestion of hepatocyte
debris might induce a similar change in macrophage phenotype.
Primary bone marrow-derived macrophages (BMDMs), widely
used to study macrophage biology in vitro (45), were cultured in
the presence and absence of cell debris generated from strain-
matched primary murine hepatocytes. Macrophage morphology
changed signiﬁcantly after coculture in keeping with ingestion of
hepatocyte debris (Fig. 7A). Hepatocyte debris alone did not at-
tach to the wells. After ingestion, BMDMs up-regulated Mmp12,
Mmp9, and Igf1 and down-regulated Thbs1 and Chi3l3 (Fig. 7B),
mirroring the phenotypic switch seen in vivo (Fig. 5 A and B).
To conﬁrm the active secretion of MMPs and determine if this
effect was a general effect of phagocytosis on macrophages in-
dependent of the type of debris, we used the well-described model
of phagocytosis of apoptotic thymocytes (46). Culture super-
natants from BMDMs fed with apoptotic thymocytes for 12 h
showed a robust increase in active MMP-9 and MMP-12 secretion
detected by gelatin zymography and Western blotting, respectively
(Fig. 7 C and D).
We then sought todeterminewhich signalingpathwaysmight link
macrophage phagocytosis with the increase in matrix-degrading
activity. MAPK signaling, speciﬁcally the ERK and p38 cascades,
is activated in macrophages after phagocytosis, and it has been
reported to regulate a number of macrophage responses (47, 48).
Using immunohistochemistry, we could identify nuclear phos-
Fig. 5. Ly-6Clo macrophages show a gene expression
proﬁle favoring scar resolution. (A and B) Microarray
analysis of inﬂammatory Ly-6Chi and restorative Ly-
6Clo hepatic macrophage populations isolated by
FACS sorting from livers 24 and 72 h after the ﬁnal
CCl4 injection, respectively. (A) Differential regula-
tion of cytokines, chemokines, chemokine receptors,
growth factors, and matrix-degrading enzymes be-
tween the inﬂammatory and restorativemacrophage
populations (expressed as fold change between the
two macrophage subsets). (B) Differential expression
of opsonins, phagocytosis-related genes, PPAR-γ tar-
get genes, and macrophage phenotype markers (M1,
classical; M2, alternative) between the macrophage
subsets on microarray (expressed as fold change be-
tween the two macrophage populations). All micro-
array data based on n = 3 per group taken from two
independent experiments. *P < 0.05, **P < 0.01,
***P < 0.001. (C) Flow cytometric analysis comparing
expression of stated marker between inﬂammatory
Ly-6Chi and restorative Ly-6Clo hepatic macrophages.
MMPsense was administered 24 h before the time
of harvest to compare MMP activity between mac-
rophage subsets expressed relative to average MFI
for inﬂammatory macrophage subset (n = 3–6). MFI,
mean ﬂuorescence intensity. *P < 0.05, **P < 0.01. (D)
Immunohistochemistry for genes differentially regu-
lated on microarray in murine liver at 24 and 72 h
time points and cirrhotic human liver (representative
images shown). (Scale bars: 100 μm.)

















pho-ERK staining in macrophages at the 72-h time point (Fig.
7E), indicating activation of the ERK signaling pathway in scar-
associated macrophages during maximal ﬁbrosis resolution. To
show a functional role for ERK signaling in the observed macro-
phage phenotype, we administered the speciﬁc ERK kinase [mi-
togen-activated protein kinase kinase 1 and 2 (MEK1/2)] inhibitor
PD98059 (50 μM) or vehicle control to BMDMs at published doses
(49, 50) for 1 h before and during feeding with hepatocyte debris in
vitro. Administration of PD98059 signiﬁcantly inhibited macro-
phage up-regulation ofMmp9,Mmp12, and Igf1 in response to the
ingestion of hepatocyte debris (Fig. 7F). Furthermore, casein
zymography on culture supernatants showed that ERK inhibition
abrogated the increase in active MMP-9 and MMP-12 secretion
observed after phagocytosis (Fig. 7G), indicating a critical role for
MEK1/2 activation in the increased matrix-degrading activity in
macrophages in response to phagocytosis. MEK1/2 inhibition
had no effect on the down-regulation of Thbs1 and Chi3l3 in
response to phagocytosis (Fig. S7A), suggesting that cross-talk
between signaling pathways is required for generating the
complex overall phenotype of the restorative macrophage. We
conﬁrmed the role of MEK1/2 in macrophage Mmp12 up-regu-
lation in response to phagocytosis using a second speciﬁc inhibitor
UO126 (20 μM) (Fig. S7B). Administration of a p38 MAPK in-
hibitor (SB203580; 10 μM) at a published dose (51) had no effect
on macrophage expression of Mmp9, Mmp12, or Igf1 in response
to phagocytosis (Fig. S7C).
These data show that the matrix-degrading phenotype of the
proresolution macrophage can be modeled in vitro by the
phagocytosis of cellular debris, and this phenotypic switch is, at
least in part, mediated by phagocytosis-related MEK1/2 activa-
tion and ERK signaling in macrophages.
Induction of Phagocytic Behavior Using Liposomes Enhances the
Restorative Macrophage Phenotype in Vivo and Accelerates Fibrosis
Resolution. Having conclusively identiﬁed macrophage phagocy-
tosis as a key determinant of the proresolution matrix-degrading
phenotype, we wished to use this information to manipulate
Fig. 6. Restorative Ly-6Clo macrophages are postphagocytic. Comparison of
inﬂammatory (24 h Ly-6Chi) and restorative (72 h Ly-6Clo) macrophage sub-
sets after 4 wk of CCl4. (A) Size [forward scatter area (FSC-A)] and complexity
[side scatter area (SSC-A)] of macrophage subsets assessed by ﬂow cytometry
expressed relative to average MFI for inﬂammatory macrophages (n = 13
from three independent experiments). (B) F4/80 immunohistochemistry shows
larger scar-associated macrophages at 72 h. (Scale bar: 50 μm.) (C–E) TUNEL
staining and confocal microscopy of FACS-sorted subsets. (C) Stained DAPI,
TUNEL, F4/80, andmerged image for macrophage subsets. (Scale bars: 10 μm.)
Arrowheads, cell-surface debris; arrows, ingested debris. (D) Percentage of
each subset associated with TUNEL-positive nuclei by cell counting (n = 3–4).
(E ) Percentage of TUNEL-associated macrophages with ingested or cell-
surface debris (n = 3–4). Data shown as mean ± SEM. *P < 0.05, **P < 0.01,
***P < 0.001. NS, nonsigniﬁcant. Representative images are shown.
Fig. 7. Macrophage phagocytosis in vitro induces a matrix-degrading phe-
notype through ERK signaling. (A and B) Coculture of BMDMs with hepa-
tocyte debris. (A) Changes in macrophage morphology on phase-contrast
microscopy. Hepatocyte debris alone was nonadherent. (B) Changes in
macrophage gene expression after coculture expressed relative to mean
expression of macrophages alone (n = 11–12 from two independent
experiments). (C and D) Coculture of BMDMs with apoptotic thymocytes. (C)
Gelatin zymography of culture supernatants equalized for protein content
showing active MMP-9 (representative zymogram from n = 4 from two in-
dependent experiments). (D) Western blot for MMP-12 on culture super-
natants equalized for protein content (representative blot from n = 4 from
two independent experiments). (E) Dual immunoﬂuorescence for F4/80 and
phospho-ERK in mouse liver 72 h after ﬁnal CCl4 dose after 4 wk of injury.
Arrows, nuclear pERK and F4/80 dual positive cells. (Scale bars: 10 μm.) (F and
G). Culture of BMDMs ± MEK1/2 inhibitor (PD98059; 50 μM) ± hepatocyte
debris. (F) Changes in macrophage gene expression after coculture ex-
pressed relative to mean expression of macrophages alone (n = 6). (G) Casein
zymography of culture supernatants equalized for protein content showing
active MMP-9 and MMP-12 (representative zymogram from n = 3 shown).
Data shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. Repre-
sentative images are shown.
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macrophage phenotype in vivo with a therapeutic beneﬁt in ac-
celerating ﬁbrosis resolution. The systemic administration of
cellular debris is likely to have signiﬁcant confounding off-target
effects. Liposome uptake by macrophages represents a genuine
phagocytosis event (52), and it has been widely used to target
macrophages in vivo. Furthermore, recent studies have shown
that liposome administration can alter macrophage phenotype in
vivo in part by induction of ERK signaling after ingestion (53,
54). We proceeded to feed BMDMs with liposomes in vitro,
which induced a change in macrophage phenotype (Fig. 8A)
analogous to the change that we observed in vivo (Fig. 5 A and
B) and similar to the tissue culture models after the ingestion of
cellular debris (Fig. 7B). Thus, ingestion of liposomes models the
phagocytosis of cellular debris and the generation of restorative
macrophages. We went on to administer liposomes (or vehicle
control) to chronically injured mice during maximal ﬁbrosis
resolution for 48, 72, and 96 h after the ﬁnal CCl4 injection, with
harvest at 120 h (Fig. 8B). In keeping with an induction of
phagocytic behavior, liposome administration caused a reduction
in proinﬂammatory Ly-6Chi macrophages and an increase in re-
storative Ly-6Clo hepatic macrophages during ﬁbrosis resolution
(Fig. 8C). Liposomes, when ﬂuorescently labeled, were rarely
detected in Ly-6Chi macrophages but frequently seen in Ly-6Clo
macrophages, indicative of a postphagocytic phenotype (Fig. 8D).
Critically, this manipulation accelerated the regression of liver
ﬁbrosis (Fig. 8 E and F), indicating that, by inducing phagocy-
tosis, macrophages could be switched to a phenotype promoting
ﬁbrosis resolution in vivo.
Discussion
In a murine model of reversible hepatic ﬁbrosis, we have used
differential Ly-6C expression to identify and characterize the
hitherto elusive restorative macrophage. This Ly-6Clo CD11Bhi
F4/80int macrophage population accumulates in the liver, and it
is the main MMP-expressing macrophage subset during maximal
ﬁbrosis resolution, is necessary for degradation of tissue scar, is
derived from inﬁltrating Ly-6Chi inﬂammatory monocytes, has
a distinct pattern of gene expression, including matrix degrada-
tion and phagocytic and growth factors, and is characterized by
evidence of prior phagocytosis of dying cells. The restorative
phenotype can be recapitulated in vitro by phagocytosis-induced
ERK signaling and can be induced in vivo by the administration
of liposomes, which accelerates scar resolution.
Although evidence for a central role for macrophages in in-
ﬂammation and tissue ﬁbrogenesis has been described across
organ systems (8), data have recently emerged to suggest a
functional heterogeneity of subtypes in vivo and a role in ﬁbrosis
resolution (3, 6, 11, 12). Differential Ly-6C expression has been
widely used to identify functionally distinct populations of cir-
culating murine monocytes (15, 16) and macrophage populations
in pathology (17–21). Our data show that Ly-6C expression can
be exploited to identify the macrophage subset responsible for
ﬁbrosis resolution. Key questions arising from studies regarding
the divergent role of macrophages in ﬁbrogenesis and recovery
were whether these distinct functions were mediated by resident
or recruited cells and whether those cells underwent a pheno-
typic switch in situ (55, 56). Herein, we have shown conclusively
that the proresolution Ly-6Clo macrophage population derives
from recruited Ly-6Chi monocytes, a common origin to the pro-
ﬁbrotic Ly-6Chi macrophage, indicating a switch in macrophage
function in vivo. This ﬁnding is in keeping with the known ability
of monocytes and macrophages to change phenotype in situ
depending on local environmental cues (13). These ﬁndings have
implications for development of antiﬁbrotic therapies, where
targeting inﬂammatory monocyte recruitment might adversely
impact on the population of restorative Ly-6Clo macrophages (39,
57). This ﬁnding provides an explanation for the apparently
counterintuitive observation made in the work by Mitchell et al.
(58): that decreased CCR2-dependent recruitment of Ly-6Chi
monocytes retards ﬁbrosis resolution (58). A more detailed study
of the signals controlling macrophage dynamics and phenotype
during ﬁbrosis resolution now depends on the development of
monocyte/macrophage-speciﬁc chemokine receptor KO trans-
genic mice, in which key genes can be inducibly deleted without
the confounding variable of differences in peak ﬁbrosis that
complicates noninducible transgenic models.
The contribution of local macrophage proliferation during
hepatic ﬁbrogenesis or ﬁbrosis resolution has not previously been
deﬁned. We have shown a high level of proliferation of proin-
ﬂammatory hepatic Ly-6Chi monoctyte-derived macrophages,
suggesting that a combination of recruitment and local pro-
liferation is required for the generation of restorative Ly-6Clo
macrophages. This ﬁnding initially seems to contrast with ﬁnd-
ings in work by Jenkins et al. (31), where resident F4/80hi pleural
macrophages proliferated during chronic parasitic infection.
However, using classical inﬂammatory stimuli, the work by Jen-
kins et al. (31) also showed the capacity of recruited monocyte-
derived macrophages to proliferate in the context of Il-4 stimu-
lation (31). Our work is, therefore, complementary to this study,
highlighting that the relative contribution of recruitment and
Fig. 8. Induction of phagocytic behavior using liposomes enhances the re-
storative macrophage phenotype in vivo and accelerates ﬁbrosis resolution.
(A) Changes in macrophage gene expression after in vitro feeding with lip-
osomes expressed relative to mean expression of unfed macrophages (n = 6).
(B) Schematic representation of the model of liposome (or vehicle) adminis-
tration during resolution phase after 4 wk of CCl4 injury. (C) Changes in he-
paticmacrophage subsets after liposome administration relative tomean total
macrophage number in vehicle-treated livers (n = 13–14). (D) Percentage of
each hepatic macrophage subset containing ﬂuorescently labeled liposomes
assessed by ﬂow cytometry (n = 8). (E) Fibrosis assessed by PSR staining after
liposome (or vehicle) administration. Representative images are shown. (Scale
bar: 100 μm.) (F) Quantiﬁcation of ﬁbrosis by morphometric pixel analysis
expressed relative to mean percent area for liposome-treated liver (n = 6).
Data shown as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.

















local proliferation to tissue macrophage expansion during in-
ﬂammation is critically dependent on the nature of injury and
organ involved. Investigators should consider this information in
future studies on macrophage dynamics.
A major difﬁculty in studying macrophage heterogeneity in
vivo is the lack of deﬁned speciﬁc markers for functionally dis-
tinct populations, necessitating the use of ﬂow cytometry on
freshly isolated tissue to recognize subsets. Thus, existing strat-
egies for macrophage depletion are unable to speciﬁcally select
for functionally distinct subsets. In this work, we used the widely
used CD11B-DTR system (11, 17). This transgenic strategy
shows selectivity for CD11Bhi F4/80lo monocytes and monocyte-
derived macrophages compared with CD11Blo F4/80hi resident
tissue macrophages. We have gone on to show that speciﬁc de-
pletion of subsets of CD11Bhi F4/80lo cells is critically dependent
on timing. Furthermore, our data indicate an increased suscep-
tibility of Ly-6Clo macrophages to depletion with DT, which is
likely to be a result of higher levels of CD11B expression in this
population. We have discovered a number of genes that are
differentially expressed by the functionally distinct populations.
These ﬁndings could inform transgenic studies, where individual
macrophage subsets could be speciﬁcally depleted or labeled in
vivo. Using these data, we could identify distinct macrophages in
situ using immunohistochemistry, enabling more easy translation
to studying human tissue. Our ﬁndings are based on the highly
tractable and predictable CCl4 model of reversible hepatic ﬁ-
brosis. To study macrophage dynamics and phenotype on a day-
by-day basis, we deliberately focused on an early ﬁbrosis, which
resolves rapidly and completely. A future goal is the more de-
tailed analysis of hepatic macrophage subsets in cirrhotic human
liver to identify analogous populations to those populations de-
scribed in this study; until this analysis is undertaken, extrapo-
lation of our ﬁndings to human models must be guarded.
The data presented also show that the switch to a proresolution
macrophage population confers a number of potential antiﬁbrotic
properties. Principally, there is a change from expression of pro-
inﬂammatory cytokines, chemokines, and proﬁbrotic genes, such
as thrombospondin-1 (34), to a proﬁle incorporating genes re-
sponsible for scar degradation, such as Mmp12 and Mmp9, genes
critical for the clearance of cellular debris, and a number of po-
tential antiﬁbrotic pathways, such as Igf1 (35) and CD74/MIF (33).
Furthermore, our data expose the limitations of categorizing
macrophage populations from an in vivo setting into the widely
used but restrictive M1/M2 paradigm. Moving forward, we
suggest that a more functional classiﬁcation of macrophage
subsets should be used to better represent their biology.
Phagocytosis can elicit signiﬁcant effects on macrophage phe-
notype and function (19, 42). By showing that the proresolution
macrophage phenotype can be promoted by ingestion of debris
and that the increase in matrix-degrading activity is mediated by
phagocytosis-induced ERK signaling, we have identiﬁed a poten-
tial therapeutic approach to manipulate these cells in situ. Cru-
cially, our data showing that the in vivo phenotypic switch can be
induced through phagocytosis of administered liposomes with a
beneﬁcial effect on ﬁbrosis resolution identify a possible trans-
lational strategy for the treatment of tissue ﬁbrosis. An attractive
alternative therapeutic strategy would be the use of macrophages
modiﬁed in vitro by feeding with liposomes to generate pro-
resolution features as a cell therapy to induce ﬁbrosis regression.
This use would require modiﬁcation of the macrophages to en-
sure adequate trafﬁcking to the ﬁbrotic liver after peripheral in-
jection, but it remains an intriguing area for additional study.
In conclusion, we have identiﬁed and characterized a speciﬁc
macrophage phenotype responsible for the resolution of tissue
ﬁbrosis. In addition to the value in studying macrophage biology,
this study has important implications for ﬁbrosis research and the
future development of antiﬁbrotic therapies aimed at targeting
macrophages in vivo.
Materials and Methods
Mice. C57BL/6 mice (CD45.2+) were purchased from Harlan. CD11B-DTR mice,
originally obtained from R. Lang, Children’s Hospital Research Foundation,
Cincinnati, OH and as previously described (11), were maintained as heter-
ozygotes on a C57BL/6 background. CD45.1+ C57BL/6 mice (59) were pro-
vided by S. M. Anderton, University of Edinburgh. CD11C-DOG mice (28)
were provided by A. S. MacDonald, University of Edinburgh. Mice were bred
under speciﬁc pathogen-free conditions at the University of Edinburgh. All
experiments had local ethical approval and were conducted under UK Home
Ofﬁce Legislation.
Liver Fibrosis Models. Adult male mice at least 6 wk of age were used. Hepatic
ﬁbrosis was induced by two times per week i.p. CCl4 (0.4 μL/g; Sigma) diluted
1:3 in olive oil (Sigma) for 4 wk (nine injections). Animals were culled at
stated time points after the ﬁnal CCl4 injection. For depletion studies, DT (10
ng/g in PBS; List Biological Laboratories) or PBS control was administered to
ﬁbrotic CD11B-DTR or WT mice i.v. through the tail vein at the stated time
points. DC depletion in ﬁbrotic CD11C-DOG mice was performed by ad-
ministration of DT (12 ng/g) or PBS control i.p. at the stated time points.
Adoptive transfer experiments were performed through the tail vein at
stated time points using (i) 9 × 105 FACS-sorted CD45.1+ Ly-6Chi monocytes
from bone marrow in RPMI 1640 or vehicle control; (ii) 250 μL ﬂuorescent latex
beads [0.5 μm Fluoresbrite polychromatic red microspheres; 2.5% solids (wt/
vol) diluted 1:25 in PBS for injection; Polysciences Inc] or vehicle control; and
(iii) 250 μL liposomes (60) (provided by N.v.R.), CM-DiI–labeled (Invitrogen)
liposomes (labeled according to the manufacturer’s protocol), or PBS control.
Flow Cytometry and FACS Sorting. Flow cytometry (using BD LSR Fortessa II) and
FACS sorting (using BD FACSAria II) were performed on hepatic nonparen-
chymal cells containing the total hepatic leukocyte population (SI Materials
and Methods). FACS sorting routinely yielded cell purity levels of over 95%.
Detection of in Vivo MMP Activity. To detect in vivo MMP activity, 2 nmol
MMPsense 680 (Perkin-Elmer) (or vehicle control) were administered to ani-
mals through the tail vein 24 h before harvest according to the manufacturer’s
protocol. Hepatic macrophages were identiﬁed using ﬂow cytometry fol-
lowed by identiﬁcation of MMPsense-positive macrophages with excitation
laser at 635 nm (23).
Microarray Analysis. Fifty nanograms RNA from FACS-sorted cells was pro-
cessed using the Ovation Pico WTA system (NuGen) according to the man-
ufacturer’s protocol (n = 3 per group). Processed RNAs were hybridized to
Affymetrix GeneChip Mouse Gene 1.0 ST Arrays. RNA/microarray processing
was carried out by ARK Genomics (Roslin Institute). Data analysis was
performed as described (SI Materials and Methods). Fold change > 2 with
adjusted P < 0.05 was considered signiﬁcant for individual gene changes.
Gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway enrichment analysis was done with the DAVID tool (36, 37) on
genes that were signiﬁcantly differentially expressed. Microarray data
are available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress)
under accession number E-MEXP-3177.
In Vitro Phagocytosis Assay. BMDMs, primary murine hepatocyte debris, and
apoptotic thymocytes were prepared as described (SI Materials and Meth-
ods); 2 × 105 BMDMs were seeded per well in 12-well plates followed by the
addition of 5 × 105 washed dead hepatocytes (or control medium) and 1 ×
106 washed dead thymocytes or liposomes at 1:10 dilution by volume (or PBS
control) cultured for 16 h (or 12 h for thymocytes) at 37 °C 5% (vol/vol) CO2
in DMEM/F12 Glutamax (Gibco) medium with 10% FCS. Where stated,
inhibitors PD98059 (50 μM; Cayman Chemical), UO126 (20 μM; New England
Biolabs), SB203580 (10 μM; Cayman Chemical), or DMSO control were added
to the plated BMDMs for 1 h before and maintained throughout the 16-h
incubation with hepatocyte debris. Supernatants were then harvested and
stored at −80 °C, noningested hepatocytes or liposomes were removed by
vigorous washing three times with PBS, and residual adherent macrophages
were used for additional analysis. In control wells containing hepatocyte
debris alone, no adherent cells were detected.
Statistical Analysis. All data are expressed as mean ± SEM. Statistical analysis
was performed using GraphPad Prism 5 software. Statistical evaluation of
multiple groups was performed using a one-way ANOVA with posthoc Tukey
test. Statistical evaluation of two groups was performed using Student t test
or Mann–Whitney test if data were not normally distributed. A value of P <
0.05 was considered statistically signiﬁcant.
E3194 | www.pnas.org/cgi/doi/10.1073/pnas.1119964109 Ramachandran et al.
Additional Methods. Additional methods are shown in SI Materials and
Methods.
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